Piramal Alternatives invests Rs.110 crore in Biodeal Pharmaceuticals for infrastructure, tech upgrade, and nutraceuticals facility.

Piramal Group's subsidiary, Piramal Alternatives, has invested Rs.110 crore in Biodeal Pharmaceuticals, a contract development and manufacturing company. The funds will be used to improve infrastructure and capacities, upgrade technology, and establish a nutraceuticals manufacturing facility. Biodeal is India's leading manufacturer of nasal sprays, catering to international and domestic pharmaceutical companies.